ZoomMed inc.
TSX VENTURE : ZMD
TSX CROISSANCE : ZMD

ZoomMed inc.

December 23, 2005 23:59 ET

ZoomMed announces the filing of an amended and restated prospectus

MONTREAL, Dec. 23 - ZoomMed Inc. ("ZoomMed") (TSX Venture
Exchange: ZMD) announces that a receipt has been issued for its amended and
restated prospectus dated December 20, 2005, which amends and restates its
final prospectus dated December 12, 2005. The purpose of the amendment and
restatement was to reduce the minimum amount of the offering from $750,000 or
3,750,000 common shares of ZoomMed to $300,000 or 1,500,000 common shares of
ZoomMed in order to facilitate a first closing prior to January 1st, 2006,
thereby enabling the subscribers to benefit from tax deductions under the SME
Growth Stock Plan, provided that such subscribers satisfy the other conditions
required under said SME Growth Stock Plan.

Furthermore, ZoomMed has obtained an advance income tax ruling from the
Ministère du Revenu du Québec indicating that the changes made to the
prospectus do not affect the advance income tax ruling dated November 22,
2005. This advance ruling confirms that the common shares of ZoomMed to be
issued pursuant to this offering will be eligible shares, upon issuance, for
inclusion in an SME Growth Stock Plan.

The first closing of the Offering is expected to take place on or about
December 30th, 2005.

ZoomMed is presently developing a new electronic tool "ZRx Prescriber",
intended to change the way drugs are prescribed and dispensed throughout
Canada. This handheld prescribing system device, equipped with tools such as a
therapeutic advisor as well as a medication interaction manager, will enable
doctors to fill prescriptions and to electronically transmit them in a fast
and secure mode. This user friendly Web product, designed for doctors, will
use the latest "Pocket PC" technologies.

The TSX Venture Exchange has not approved and does not accept any
responsibility with respect to the adequacy or accuracy of this release.

Contact Information

  • Yves Marmet
    President and Chief Executive
    Officer
    (450) 678-5457